TICKERNERD
Menu
ANVSANVSHealthcare · Biotechnology

ANVS Stock Forecast: Annovis Bio, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.13
+10.78% on the day

The 4 Wall Street analysts covering Annovis Bio, Inc. hold a median 12-month price target of $9 — +696.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$48.2M
Ticker Nerd rank
27/ 100
Median analyst target
$9.00
Analysts covering
4
Revenue$0.0
Operating income−$14.4M
Net income−$14.8M
Free cash flow−$21.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.0%
1M
−11.0%
YTD
−67.3%
1Y
−45.7%
From 52W high
−77.8%
From 52W low
+17.7%
$0.96
$5.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Annovis Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
80
Accruals
67
Revisions
66
Quality
30
Issuance
28
Value
25
Growth
24
Volatility
17
Momentum
15

Size (80): Smaller than most of the companies we track.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ANVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26ANVSHigh $17.00Median $9.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $7.00Median $9.00High $17.00

The green dot is the last close — the median target sits +696.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Aug 2026Roth CapitalMaintainsBuy$8.00 → $7.00
18 Aug 2026Canaccord GenuityMaintainsBuy$17
18 Aug 2026Canaccord GenuityMaintainsBuy—
8 July 2026Roth CapitalInitiatesBuy$8.00
8 July 2026Roth CapitalInitiatesBuy—
14 Apr 2026Canaccord GenuityMaintainsBuy—
30 Sept 2025Canaccord GenuityMaintainsBuy—
3 Sept 2025HC Wainwright & Co.MaintainsBuy—
9 June 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025Canaccord GenuityMaintainsBuy—
10 Feb 2025D. Boral CapitalDowngradeHold—
11 Nov 2024D. Boral CapitalMaintainsBuy—
11 Nov 2024HC Wainwright & Co.ReiteratesBuy—
25 Oct 2024Maxim GroupUpgradeBuy—
16 Oct 2024HC Wainwright & Co.ReiteratesBuy$30
15 Oct 2024EF HuttonMaintainsBuy$21
1 Oct 2024HC Wainwright & Co.ReiteratesBuy$30
15 Aug 2024EF HuttonMaintainsBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
13 Aug 2024EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ANVS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ANVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Annovis Bio, Inc. returned −45.7% against +12.4% for the S&P 500, dividends included.

ANVS vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26ANVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Annovis Bio, Inc. (ANVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.8×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
−10.1×

Cheaper than 98% of US stocks

EV / EBITDA
−0.8×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−703.7%

Higher than 2% of US stocks

Return on assets
−142.4%

Higher than 1% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Annovis Bio, Inc. (ANVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Annovis Bio, Inc. has a market value of $48.2M and an enterprise value of $24.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$49.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$43.3M.

  • Shares outstanding: 42.6M.

  • Trailing P/E: −0.8×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Annovis Bio, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ANVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANVSAnnovis Bio, Inc.$48.2M27
HOWLWerewolf Therapeutics, Inc.$47.9M87
GANXGain Therapeutics, Inc.$47.7M27
IMAImageneBio, Inc.$48.4M28
HYPDHyperion DeFi, Inc.$48.8M42
SERSerina Therapeutics, Inc.$49.3M19
IBIOiBio, Inc.$46.8M22

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Annovis Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANVS news & analysis

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

GlobeNewsWire · 30 Oct 2026negative

Annovis Bio said it received notice from the NYSE on October 29, 2026, that it is not in compliance with continued listing standards. The notice cited average market capitalization below $50 million over 30 consecutive trading days while stockholders’ equity was also below $50 million.

Why it matters — The notice concerns the company’s compliance with NYSE listing standards, an exchange-status matter for ANVS watchers.

Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026

GlobeNewsWire · 29 Oct 2026neutral

Annovis Bio announced that Founder, President and CEO Maria Maccecchini will participate and present at two industry events in November: U.S. Biotech Day 2026 and Pharma Partnering Summit 2026.

Why it matters — The announcement informs ANVS watchers about the company’s planned executive participation at upcoming industry events.

Annovis to Attend the CTAD 2026 with Three Presentations

GlobeNewsWire · 22 Oct 2026positive

Annovis Bio announced it will attend and present at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place November 16–19 in Boston. The headline states the company will deliver three presentations.

Why it matters — The conference presentations are an opportunity for ANVS watchers to follow company updates on its work in neurodegenerative diseases.

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease

GlobeNewsWire · 23 Sept 2026positive

Annovis Bio announced a collaboration with Weave Bio, an AI regulatory content and knowledge management platform, to support preparation of the planned New Drug Application (NDA) for its investigational therapy buntanetap in Alzheimer's disease. The company is a Phase 3 clinical-stage biotech developing buntanetap for neurodegenerative diseases.

Why it matters — This partnership signals progress in Annovis's regulatory preparation for the buntanetap NDA filing in Alzheimer's disease, a key development milestone for the company.

Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Investment Research · 8 Sept 2026positive

Annovis Bio (ANVS) has fallen 26.5% over the past four weeks and is now technically oversold, suggesting heavy selling pressure has been exhausted. Strong agreement among Wall Street analysts in revising earnings estimates higher indicates a potential trend reversal for the stock in the near term.

Why it matters — A shareholder would care because an oversold condition combined with upward analyst estimate revisions points to a possible near-term reversal in the stock's direction.

FAQ

Frequently asked questions about ANVS stock

What is the ANVS stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Annovis Bio, Inc. have a median 12-month price target of $9, with estimates ranging from $7 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANVS stock a buy right now?

Of the 4 analysts covering Annovis Bio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Annovis Bio, Inc. 27 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANVS?

As at 31 Oct 2026, Annovis Bio, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (80 of 100).

Will ANVS stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +696.5% from the last close, and Ticker Nerd's factor model ranks Annovis Bio, Inc. 27 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANVS stock forecast for 2030?

No analyst covering Annovis Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANVS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $17 over the next 12 months.

How has ANVS stock performed over the past year?

Annovis Bio, Inc. returned -45.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Annovis Bio, Inc. do?

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.

What is the latest news on ANVS?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE". Annovis Bio said it received notice from the NYSE on October 29, 2026, that it is not in compliance with continued listing standards. The notice cited average market capitalization below $50 million over 30 consecutive trading days while stockholders’ equity was also below $50 million.

Company

About Annovis Bio, Inc.

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. Its current pipeline centers on oral small-molecule candidates designed to address disorders such as Alzheimer’s disease and Parkinson’s disease, with additional programs targeting traumatic brain injury, stroke, Lewy body dementia, and advanced Alzheimer’s disease. The company’s lead candidate, buntanetap, is being studied for chronic neurodegeneration, while ANVS405 and ANVS301 extend its research into acute and later-stage neurological conditions. Annovis Bio’s work is directed at central nervous system disorders where protein misfolding, neuroinflammation, and cognitive decline play key roles. Based in Malvern, Pennsylvania, Annovis Bio operates as a research-driven drug development company within the biotechnology sector.

CEO Dr. Maria L. Maccecchini Ph.D. · 7 employees · United States · https://www.annovisbio.com